Long-term plasticity of endocannabinoid signaling induced by developmental febrile seizures

Neuron

Volumn 39, Issue 4, 2003, Pages 599-611

  Chen, Kang ^a   Ratzliff, Anna ^a   Hilgenberg, Lutz ^a   Gulyás, Attila ^a,d   Freund, Tamás F ^d   Smith, Martin ^a   Dinh, Thien P ^b   Piomelli, Daniele ^b   Mackie, Ken ^c   Soltesz, Ivan ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

^d INSTITUTE OF EXPERIMENTAL MEDICINE   (Hungary)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID; CANNABINOID; CANNABINOID 1 RECEPTOR; CHOLECYSTOKININ; GLUTAMIC ACID; PRESYNAPTIC RECEPTOR;

4 AMINOBUTYRIC ACID UPTAKE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN SLICE; CONTROLLED STUDY; DEVELOPMENTAL DISORDER; FEBRILE CONVULSION; HIPPOCAMPUS; HYPERTHERMIA; NERVE CELL PLASTICITY; NEUROTRANSMITTER RELEASE; NEWBORN; NONHUMAN; POSTNATAL DEVELOPMENT; PRIORITY JOURNAL; RAT; RECEPTOR DENSITY; RECEPTOR UPREGULATION; SIGNAL TRANSDUCTION;

EID: 0043023379     PISSN: 08966273     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0896-6273(03)00499-9     Document Type: Article

References (48)

1. Ameri A., Wilhelm A., Simmet T. Effects of the endogenous cannabinoid, anandamide, on neuronal activity in rat hippocampal slices. Br. J. Pharmacol. 126:1999;1831-1839.
2. A-receptor-mediated IPSPs after epileptiform burst discharges in CA1 pyramidal cells. J. Neurophysiol. 79:1998;659-669.
3. Beltramo M., Stella N., Calignano A., Lin S.Y., Makriyannis A., Piomelli D. Functional role of high-affinity anandamide transport, as revealed by selective inhibition. Science. 277:1997;1094-1097.
4. Bouaboula M., Perrachon S., Milligan L., Canat X., Rinaldi-Carmona M., Portier M., Barth F., Calandra B., Pecceu F., Lupker J.et al. A selective inverse agonist for central cannabinoid receptor inhibits mitogen-activated protein kinase activation stimulated by insulin or insulin-like growth factor 1. Evidence for a new model of receptor/ligand interactions. J. Biol. Chem. 272:1997;22330-22339.
5. A receptor subunit expression and function in temporal lobe epilepsy. Nat. Med. 4:1998;1166-1172.
6. Chen H., Lambert N.A. Endogenous regulators of G protein signaling proteins regulate presynaptic inhibition at rat hippocampal synapses. Proc. Natl. Acad. Sci. USA. 97:2000;12810-12815.
7. Chen K., Baram T.Z., Soltesz I. Febrile seizures in the developing brain result in persistent modification of neuronal excitability in limbic circuits. Nat. Med. 5:1999;888-894.
8. Chen K., Aradi I., Thon N., Eghbal-Ahmadi M., Baram T.Z., Soltesz I. Persistently modified h-channels after complex febrile seizures convert the seizure-induced enhancement of inhibition to hyperexcitability. Nat. Med. 7:2001;331-336.
9. Chevaleyre V., Castillo P.E. Heterosynaptic LTD of hippocampal GABAergic synapses. a novel role of endocannabinoids in regulating excitability Neuron. 38:2003;461-472.
10. Clement A.B., Hawkins E.G., Lichtman A.H., Cravatt B.F. Increased seizure susceptibility and proconvulsant activity of anandamide in mice lacking fatty acid amide hydrolase. J. Neurosci. 23:2003;3916-3923.
11. Cravatt B.F., Giang D.K., Mayfield S.P., Boger D.L., Lerner R.A., Gilula N.B. Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides. Nature. 384:1996;83-87.
12. Desarnaud F., Cadas H., Piomelli D. Anandamide amidohydrolase activity in rat brain microsomes. Identification and partial characterization. J. Biol. Chem. 270:1995;6030-6035.
13. Di Marzo V., Fontana A., Cadas H., Schinelli S., Cimino G., Schwartz J.C., Piomelli D. Formation and inactivation of endogenous cannabinoid anandamide in central neurons. Nature. 372:1994;686-691.
14. Dinh T.P., Carpenter D., Leslie F.M., Freund T.F., Katona I., Sensi S.L., Kathuria S., Piomelli D. Brain monoglyceride lipase participating in endocannabinoid inactivation. Proc. Natl. Acad. Sci. USA. 99:2002;10819-10824.
15. Egertová M., Giang D.K., Cravatt B.F., Elphick M.R. A new perspective on cannabinoid signalling. complementary localization of fatty acid amide hydrolase and the CB1 receptor in rat brain Proc. R. Soc. Lond. B. Biol. Sci. 265:1998;2081-2085.
16. Fitzjohn S.M., Bortolotto Z.A., Palmer M.J., Doherty A.J., Ornstein P.L., Schoepp D.D., Kingston A.E., Lodge D., Collingridge G.L. The potent mGlu receptor antagonist LY341495 identifies roles for both cloned and novel mGlu receptors in hippocampal synaptic plasticity. Neuropharmacology. 37:1998;1445-1458.
17. Giuffrida A., Rodriguez de Fonseca F., Piomelli D. Quantification of bioactive acylethanolamides in rat plasma by electrospray mass spectrometry. Anal. Biochem. 280:2000;87-93.
18. Hájos N., Freund T.F. Pharmacological separation of cannabinoid sensitive receptors on hippocampal excitatory and inhibitory fibers. Neuropharmacology. 43:2002;503-510.
19. Hájos N., Katona I., Naiem S.S., MacKie K., Ledent C., Mody I., Freund T.F. Cannabinoids inhibit hippocampal GABAergic transmission and network oscillations. Eur. J. Neurosci. 12:2000;3239-3249.
20. Hampson R.E., Zhuang S.-Y., Weiner J.L., Deadwyler S.A. Functional significance of cannabinoid-mediated, depolarization-induced suppression of inhibition (DSI) in the hippocampus. J. Neurophysiol. 90:2003;55-65.
21. Hoffman A.F., Lupica C.R. Mechanisms of cannabinoid inhibition of GABA(A) synaptic transmission in the hippocampus. J. Neurosci. 20:2000;2470-2479.
22. Freund T.F., Buzsáki G. Interneurons of the hippocampus. Hippocampus. 6:1996;347-470.
23. Holmes G.L., Ben-Ari Y. Seizures in the developing brain. Perhaps not so benign after all Neuron. 21:1998;1231-1234.
24. Kathuria S., Gaetani S., Fegley D., Valino F., Duranti A., Tontini A., Mor M., Tarzia G., Rana G.L., Calignano A.et al. Modulation of anxiety through blockade of anandamide hydrolysis. Nat. Med. 9:2003;76-81.
25. Katona I., Sperlagh B., Sik A., Kafalvi A., Vizi E.S., Mackie K., Freund T.F. Presynaptically located CB1 cannabinoid receptors regulate GABA release from axon terminals of specific hippocampal interneurons. J. Neurosci. 19:1999;4544-4558.
26. Katona I., Sperlagh B., Magloczky Z., Santha E., Kofalvi A., Czirjak S., Mackie K., Vizi E.S., Freund T.F. GABAergic interneurons are the targets of cannabinoid actions in the human hippocampus. Neuroscience. 100:2000;797-804.
27. Kim J., Isokawa M., Ledent C., Alger B.E. Activation of muscarinic acetylcholine receptors enhances the release of endogenous cannabinoids in the hippocampus. J. Neurosci. 22:2002;10182-10191.
28. Kreitzer A.C., Regehr W.G. Retrograde inhibition of presynaptic calcium influx by endogenous cannabinoids at excitatory synapses onto Purkinje cells. Neuron. 29:2001;717-727.
29. McBain C.J., Fisahn A. Interneurons unbound. Nat. Rev. Neurosci. 2:2001;11-23.
30. Nusser Z., Hájos N., Somogyi P., Mody I. Increased number of synaptic GABA(A) receptors underlies potentiation at hippocampal inhibitory synapses. Nature. 395:1998;172-177.
31. Ohno-Shosaku T., Maejima T., Kano M. Endogenous cannabinoids mediate retrograde signals from depolarized postsynaptic neurons to presynaptic terminals. Neuron. 29:2001;729-738.
32. Ohno-Shosaku T., Tsubokawa H., Mizushima I., Yoneda N., Zimmer A., Kano M. Presynaptic cannabinoid sensitivity is a major determinant of depolarization-induced retrograde suppression at hippocampal synapses. J. Neurosci. 22:2002;3864-3872.
33. 2+ currents by reversal of tonic CB1 cannabinoid receptor activity. Mol. Pharmacol. 54:1998;1064-1072.
34. Piomelli D., Giuffrida A., Calignano A., Rodriguez de Fonseca F. The endocannabinoid system as a target for therapeutic drugs. Trends Pharmacol. Sci. 21:2000;218-224.
35. A responses in hippocampal pyramidal cells. J. Neurosci. 12:1992;4122-4132.
36. Rinaldi-Carmona M., Barth F., Heaulme M., Shire D., Calandra B., Congy C., Martinez S., Maruani J., Neliat G., Caput D., Ferrara P., Soubrie P., Breliere J.C., Le Fur G. SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett. 350:1994;240-244.
37. Shinnar S. Prolonged febrile seizures and mesial temporal sclerosis. Ann. Neurol. 43:1998;411-412.
38. Stella N., Schweitzer P., Piomelli D. A second endogenous cannabinoid that modulates long-term potentiation. Nature. 388:1997;773-778.
39. Toth Z., Xiao-Xin Y., Haftoglou S., Ribak C.E., Baram T.Z. Seizure-induced neuronal injury. vulnerability to febrile seizures in an immature rat model J. Neurosci. 18:1998;4285-4294.
40. Tsou K., Mackie K., Sanudo-Pena M.C., Walker J.M. Cannabinoid CB1 receptors are localized primarily on cholecystokinin-containing GABAergic interneurons in the rat hippocampal formation. Neuroscience. 93:1999;969-975.
41. Varma N., Carlson G.C., Ledent C., Alger B.E. Metabotropic glutamate receptors drive the endocannabinoid system in hippocampus. J. Neurosci. 21:2001;RC188.
42. Varma N., Brager D., Morishita W., Lenz R.A., London B., Alger B. Presynaptic factors in the regulation of DSI expression in hippocampus. Neuropharmacology. 43:2002;550-562.
43. Vasquez C., Lewis D.L. The CB1 cannabinoid receptor can sequester G-proteins, making them unavailable to couple to other receptors. J. Neurosci. 19:1999;9271-9280.
44. Walker M.C., Kullmann D.M. Febrile convulsions. a 'benign' condition? Nat. Med. 5:1999;871-872.
45. Wallace M.J., Martin B.R., DeLorenzo R.J. Evidence for a physiological role of endocannabinoids in the modulation of seizure threshold and severity. Eur. J. Pharmacol. 452:2002;295-301.
46. West M.J. Stereological methods for estimating the total number of neurons and synapses. issues of precision and bias Trends Neurosci. 22:1999;51-61.
47. Wilson R.I., Nicoll R.A. Endogenous cannabinoids mediate retrograde signalling at hippocampal synapses. Nature. 410:2001;588-592.
48. Wilson R.I., Kunos G., Nicoll R.A. Presynaptic specificity of endocannabinoid signaling in the hippocampus. Neuron. 31:2001;453-462.